Biotech startups in San Diego, California
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Avenzo Therapeutics | San Diego | Series B | $60.0M | 2025-09-04 |
| Element Biosciences | San Diego | Series E | $277.0M | 2026-06-09 |
| Human Longevity | San Diego | Series B | $39.8M | 2024-08-21 |
| Condor Software | San Diego | Series A | $24.0M | 2026-03-18 |
| Zafrens | San Diego | Series A | $6.0M | 2026-11-03 |
| Gallant | San Diego | Series B | $18.0M | 2025-03-15 |
| Capstan Therapeutics | San Diego | Series B | $175.0M | 2024-03-20 |
| BlossomHill Therapeutics | San Diego | Series B | $84.0M | 2025-12-10 |
8 rows of the CSV in 5 of its 18 columns.
- The 231 biotech startups in San Diego, California have raised $14.8B in total.
- 30 of them closed their most recent round in the last 12 months, $1.9B combined.
- The largest of those rounds is Element Biosciences' $277.0M Series E, dated June 2026.
- The most recent is Zafrens' $6.0M Series A on 3 November 2026.
- OrbiMed is an investor in 6 of them, more than any other fund.
- Health care is the most common other sector, with 196 companies (85%).
- 30% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (49% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
24 of 231| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
| Rybodyn | Rybodyn develops therapeutics that train the immune system to detect and eradicate cancer. | Biotech | Seed | $1.3M | 2026-07-23 | $15.3M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2022 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| Condor Software | Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. | Biotech | Series A | $24.0M | 2026-03-18 | $29.5M | Plug and Play, MassChallenge, Pareto Holdings +1 | 11 to 50 | 2020 |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| Avenzo Therapeutics | Avenzo Therapeutics develops oncology therapies for treating cancer. | Biotech | Series B | $60.0M | 2025-09-04 | $841.9M | New Enterprise Associates, Sands Capital Ventures, Lilly Asia Ventures +2 | 11 to 50 | 2022 |
| Arthrosi Therapeutics | Arthrosi Therapeutics develops pharmaceutical treatments through clinical research and drug development programs. | Biotech | Series E | $153.0M | 2025-06-23 | $277.4M | Viva BioInnovator, Xiamen Changrong Investment Management, Viva Ventures Biotech Fund | 11 to 50 | 2018 |
| Actio Biosciences | Actio Biosciences develops drugs for rare diseases through its research center. | Biotech | Series B | $66.0M | 2025-06-18 | $121.0M | Canaan Partners, Euclidean Capital, Deerfield Management +2 | 11 to 50 | 2021 |
| Sirius Therapeutics | Sirius Therapeutics is a biotechnology company developing RNAi therapies for cardiovascular diseases. | Biotech | Series B | $50.0M | 2025-05-09 | $110.0M | OrbiMed, Hankang Capital, Creacion Ventures +1 | 11 to 50 | 2021 |
| Biolinq | Biolinq develops a wearable biosensor platform that measures blood level information. | Biotech | Series C | $100.0M | 2025-03-19 | $276.3M | Alpha Wave Global, Pegasus Tech Ventures, M Ventures | 51 to 100 | 2012 |
| Gallant | Gallant advances investigational stem cell therapies to extend the healthy years of pets. | Biotech | Series B | $18.0M | 2025-03-15 | $44.0M | Alumni Ventures, Bling Capital, Science +2 | 11 to 50 | 2018 |
| BioSapien | BioSapien is a biotech startup that provides a drug delivery platform for cancer treatment. | Biotech | Seed | $8.0M | 2024-12-13 | $45.1M | SOSV, National Science Foundation, SOSV SF & NY (Fka IndieBio) +2 | 1 to 10 | 2018 |
| Human Longevity Unicorn | Human Longevity is a genomics-based health intelligence company supporting proactive healthcare. | Biotech | Series B | $39.8M | 2024-08-21 | $369.8M | StartUp Health, Amino Capital, Threshold +1 | 51 to 100 | 2013 |
| Autobahn Therapeutics | Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. | Biotech | Series C | $100.0M | 2024-07-24 | $208.7M | Insight Partners, Invus, Bristol-Myers Squibb +2 | 11 to 50 | 2017 |
| Truvian Sciences | Truvian Sciences develops an automated benchtop system for lab-accurate blood testing. | Biotech | Series D | $74.0M | 2024-07-17 | $208.1M | General Catalyst, GreatPoint Ventures, Tao Capital Partners +2 | 101 to 250 | 2015 |
| Aardvark Therapeutics | Aardvark Therapeutics develops small molecule drugs for obesity and rare genetic metabolic disorders. | Biotech | Series C | $85.0M | 2024-05-09 | $129.0M | Cormorant Asset Management, Vickers Venture Partners, Decheng Capital +1 | 11 to 50 | 2017 |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| CRISPR QC | CRISPR QC provides an analytics platform that delivers insights for biotechnology research. | Biotech | Series A | $10.0M | 2024-01-04 | $12.5M | Serra Ventures, Xcellerant Ventures | 11 to 50 | 2021 |
| MBrace Therapeutics | MBrace Therapeutics is a privately held biopharmaceutical company. | Biotech | Series B | $85.0M | 2023-11-14 | $110.0M | Venrock, TPG, Alta Partners +2 | 11 to 50 | 2019 |
| Tentarix Biotherapeutics | Tentarix Biotherapeutics creates protein therapeutics with combined bioactivities using synthetic biology. | Biotech | Series B | $35.0M | 2023-09-06 | $93.0M | Versant Ventures, Samsara BioCapital, Amplitude Venture Capital | 11 to 50 | 2020 |
| Persephone Biosciences | Persephone Biosciences uses artificial intelligence to develop microbial-based immunotherapies for cancer. | Artificial intelligence | Seed | $15.0M | 2022-07-19 | $15.1M | Y Combinator, Pioneer Fund, ZhenFund +2 | 11 to 50 | 2017 |
| Liquid Grids | Liquid Grids helps healthcare companies monitor and engage in online health conversations. | Biotech | Series A | $699K | 2016-04-25 | $5.5M | TCA Venture Group, EvoNexus, Miramar Ventures | 11 to 50 | 2010 |
Table 1. Biotech startups in San Diego, California: the 24 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 231.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| 2 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 3 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 4 | BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| 5 | Condor Software | Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. | Biotech | Series A | $24.0M | 2026-03-18 | $29.5M | Plug and Play, MassChallenge, Pareto Holdings +1 | 11 to 50 | 2020 |
| 6 | Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
| 7 | Rybodyn | Rybodyn develops therapeutics that train the immune system to detect and eradicate cancer. | Biotech | Seed | $1.3M | 2026-07-23 | $15.3M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2022 |
Table 2. Biotech startups in San Diego, California: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed | Private equity firm | New York, United States | 6 | 3% | 3 | Mirador Therapeutics, BlossomHill Therapeutics, Aspen Neuroscience |
| 2 | SOSV | Venture capital firm | Princeton, United States | 4 | 2% | 1 | Rybodyn |
| 3 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 3 | 1% | 1 | Aspen Neuroscience |
| 4 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 3 | 1% | 1 | Rybodyn |
| 5 | Blue Owl | Private equity firm | New York, United States | 3 | 1% | 1 | Mirador Therapeutics |
| 6 | EvoNexus | Startup accelerator | La Jolla, United States | 3 | 1% | ||
| 7 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 2 | 1% | ||
| 8 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 2 | 1% | ||
| 9 | Fidelity | Investment bank | Boston, United States | 2 | 1% | 2 | Element Biosciences, Mirador Therapeutics |
| 10 | RA Capital Management | Startup incubator | Boston, United States | 2 | 1% | 1 | Element Biosciences |
| 11 | Digitalis Ventures | Venture capital firm | New York, United States | 2 | 1% | ||
| 12 | Bold Capital Partners | Venture capital firm | Santa Monica, United States | 2 | 1% | ||
| 13 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 2 | 1% | ||
| 14 | Cormorant Asset Management | Hedge fund | Boston, United States | 2 | 1% | 1 | BlossomHill Therapeutics |
| 15 | S32 | Venture capital firm | San Diego, United States | 2 | 1% | 1 | Aspen Neuroscience |
Table 3. Biotech startups in San Diego, California: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 196 | 85% | $14.0B |
| Software | 24 | 10% | $150.0M |
| Artificial intelligence | 14 | 6% | $108.3M |
| Hardware | 6 | 3% | $319.0M |
| Fintech | 2 | 1% | $29.5M |
| Energy | 2 | 1% | |
| Education | 1 | 0% | $3.3M |
| Commerce | 1 | 0% |
Table 4. Biotech startups in San Diego, California by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in San Diego, California by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 3% | $6.0M |
| October 2026 | 4 | 13% | $170.8M |
| September 2026 | 2 | 7% | $50.0M |
| August 2026 | 2 | 7% | $76.0M |
| July 2026 | 5 | 17% | $134.6M |
| June 2026 | 2 | 7% | $277.0M |
| May 2026 | 3 | 10% | $240.5M |
| April 2026 | 3 | 10% | $241.3M |
| March 2026 | 2 | 7% | $55.9M |
| January 2026 | 3 | 10% | $273.3M |
| December 2025 | 2 | 7% | $214.0M |
| November 2025 | 1 | 3% | $115.0M |
Table 6. Biotech startups in San Diego, California: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 27 | 12% | $1.5B |
| 2025 | 26 | 11% | $1.3B |
| 2024 | 26 | 11% | $970.9M |
| 2023 | 17 | 7% | $445.3M |
| 2022 | 14 | 6% | $564.0M |
| 2021 | 19 | 8% | $583.8M |
Table 7. Biotech startups in San Diego, California by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 24 | 10% |
| 2020 to 2022 | 45 | 20% |
| 2015 to 2019 | 69 | 30% |
| 2010 to 2014 | 41 | 18% |
| Before 2010 | 50 | 22% |
Table 8. Biotech startups in San Diego, California by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 76 | 34% |
| 11 to 50 | 108 | 49% |
| 51 to 100 | 20 | 9% |
| 101 to 250 | 10 | 5% |
| 251 to 500 | 4 | 2% |
| 501 to 1,000 | 2 | 1% |
| 1,001 to 5,000 | 1 | 0% |
| 5,001 to 10,000 | 1 | 0% |
Table 9. Biotech startups in San Diego, California by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in San Diego, California. On 16 November 2026 that is 231 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 24 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 231 rows: 36 have no round amount, 0 no city and 36 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in San Diego, California are on the list?
- 231, in the file dated 16 November 2026. 30 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 231 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.